Skip to content

Finerenone (Kerendia, BAY94-8862)

DRUG9 trials

Sponsors

Bayer

Conditions

ChildrenChronic Kidney DiseaseHeart Failure (Pediatric)Left Ventricular Systolic DysfunctionProteinuriaType 2 DiabetesType 2 Diabetes Mellitus

Phase 2

Phase 3

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Active, not recruitingNCT05196035
BayerChronic Kidney Disease, Proteinuria
Start: 2022-03-28End: 2027-05-10Target: 219Updated: 2026-08-28
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RecruitingNCT05457283
BayerChildren, Chronic Kidney Disease, Proteinuria
Start: 2022-11-08End: 2028-08-31Target: 100Updated: 2026-09-16
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
RecruitingNCT07188805
BayerHeart Failure (Pediatric), Left Ventricular Systolic Dysfunction
Start: 2025-11-19End: 2029-12-30Target: 111Updated: 2026-06-15
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
RecruitingNCT07192952
BayerHeart Failure (Pediatric), Left Ventricular Systolic Dysfunction
Start: 2026-06-01End: 2030-12-30Target: 117Updated: 2026-06-29

Phase 4

Unknown Phase

Related Papers